Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience Inc.

In a dramatic turn of events, Skye Bioscience, Inc. finds itself at the center of a class action lawsuit, accused of misleading investors about the...

Skye Bioscience Faces Lawsuit Over Misleading Claims

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report) and Skye Bioscience...

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Skye Bioscience, with a price target of $10.00. According to TipR...

Oppenheimer Sticks to Their Buy Rating for Skye Bioscience (SKYE)

Skye Bioscience, Inc. (($SKYE)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call from Skye Bios...

Skye Bioscience Earnings Call: Mixed Signals with Promising Results

Skye Bioscience, Inc. ( ($SKYE) ) has released its Q3 earnings. Here is a breakdown of the information Skye Bioscience, Inc. presented to its inves...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SKYE	$1.17	-6.80%	326.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SKYE	$1.17	-6.8%	326.88K
3
4
5
6

SKYE

SKYE

No Data Available

Get Skye Bioscience Inc. Data in Excel

Get Skye Bioscience Inc. Data in Excel